CN104840436A - Medicine composition - Google Patents
Medicine composition Download PDFInfo
- Publication number
- CN104840436A CN104840436A CN201510320016.5A CN201510320016A CN104840436A CN 104840436 A CN104840436 A CN 104840436A CN 201510320016 A CN201510320016 A CN 201510320016A CN 104840436 A CN104840436 A CN 104840436A
- Authority
- CN
- China
- Prior art keywords
- terazosin
- pharmaceutical composition
- acid
- excipient
- injectable powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 239000003814 drug Substances 0.000 title abstract description 13
- 229940079593 drug Drugs 0.000 title description 4
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 claims abstract description 169
- 229960001693 terazosin Drugs 0.000 claims abstract description 163
- 238000000034 method Methods 0.000 claims abstract description 102
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 58
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 38
- 229920000159 gelatin Polymers 0.000 claims abstract description 36
- 235000019322 gelatine Nutrition 0.000 claims abstract description 36
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 33
- 229930195725 Mannitol Natural products 0.000 claims abstract description 33
- 239000000594 mannitol Substances 0.000 claims abstract description 33
- 235000010355 mannitol Nutrition 0.000 claims abstract description 33
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 20
- 239000008101 lactose Substances 0.000 claims abstract description 20
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims abstract description 19
- 239000004471 Glycine Substances 0.000 claims abstract description 18
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims abstract description 12
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims abstract description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 12
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims abstract description 12
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 12
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 12
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims abstract description 12
- 239000008103 glucose Substances 0.000 claims abstract description 12
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000000600 sorbitol Substances 0.000 claims abstract description 12
- 239000000811 xylitol Substances 0.000 claims abstract description 12
- 235000010447 xylitol Nutrition 0.000 claims abstract description 12
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 12
- 229960002675 xylitol Drugs 0.000 claims abstract description 12
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims abstract description 11
- 235000010489 acacia gum Nutrition 0.000 claims abstract description 8
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims abstract description 7
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000004375 Dextrin Substances 0.000 claims abstract description 7
- 229920001353 Dextrin Polymers 0.000 claims abstract description 7
- 229920002907 Guar gum Polymers 0.000 claims abstract description 7
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims abstract description 7
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 7
- 229920001615 Tragacanth Polymers 0.000 claims abstract description 7
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims abstract description 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229940072056 alginate Drugs 0.000 claims abstract description 7
- 229920000615 alginic acid Polymers 0.000 claims abstract description 7
- 229960001631 carbomer Drugs 0.000 claims abstract description 7
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 7
- 235000019425 dextrin Nutrition 0.000 claims abstract description 7
- 235000010417 guar gum Nutrition 0.000 claims abstract description 7
- 239000000665 guar gum Substances 0.000 claims abstract description 7
- 229960002154 guar gum Drugs 0.000 claims abstract description 7
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims abstract description 7
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims abstract description 7
- 235000010987 pectin Nutrition 0.000 claims abstract description 7
- 239000001814 pectin Substances 0.000 claims abstract description 7
- 229920001277 pectin Polymers 0.000 claims abstract description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 7
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims abstract description 7
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims abstract description 7
- 235000010493 xanthan gum Nutrition 0.000 claims abstract description 7
- 239000000230 xanthan gum Substances 0.000 claims abstract description 7
- 229920001285 xanthan gum Polymers 0.000 claims abstract description 7
- 229940082509 xanthan gum Drugs 0.000 claims abstract description 7
- 239000000843 powder Substances 0.000 claims description 116
- 239000008194 pharmaceutical composition Substances 0.000 claims description 80
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 79
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 73
- 239000000243 solution Substances 0.000 claims description 71
- 238000001914 filtration Methods 0.000 claims description 64
- 238000004108 freeze drying Methods 0.000 claims description 64
- 239000007788 liquid Substances 0.000 claims description 58
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 50
- 239000003607 modifier Substances 0.000 claims description 42
- 239000008215 water for injection Substances 0.000 claims description 39
- 238000003756 stirring Methods 0.000 claims description 37
- 108010010803 Gelatin Proteins 0.000 claims description 34
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 34
- 239000008273 gelatin Substances 0.000 claims description 34
- 235000011852 gelatine desserts Nutrition 0.000 claims description 34
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 claims description 31
- 239000012535 impurity Substances 0.000 claims description 26
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 24
- 239000004695 Polyether sulfone Substances 0.000 claims description 20
- 229920006393 polyether sulfone Polymers 0.000 claims description 20
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- 238000005262 decarbonization Methods 0.000 claims description 16
- KKCIOUWDFWQUBT-UHFFFAOYSA-N thyronine Chemical compound C1=CC(CC(N)C(O)=O)=CC=C1OC1=CC=C(O)C=C1 KKCIOUWDFWQUBT-UHFFFAOYSA-N 0.000 claims description 16
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 13
- 235000011121 sodium hydroxide Nutrition 0.000 claims description 13
- -1 acacin Polymers 0.000 claims description 12
- 239000012467 final product Substances 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 11
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 10
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 10
- 238000005261 decarburization Methods 0.000 claims description 10
- 239000000413 hydrolysate Substances 0.000 claims description 9
- 108010009736 Protein Hydrolysates Proteins 0.000 claims description 8
- 239000012453 solvate Substances 0.000 claims description 8
- 241000416162 Astragalus gummifer Species 0.000 claims description 6
- 235000010443 alginic acid Nutrition 0.000 claims description 6
- 235000010487 tragacanth Nutrition 0.000 claims description 6
- 239000000196 tragacanth Substances 0.000 claims description 6
- 229940116362 tragacanth Drugs 0.000 claims description 6
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 5
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 5
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 5
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 5
- 235000019800 disodium phosphate Nutrition 0.000 claims description 5
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 5
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 5
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 5
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 5
- 229910017604 nitric acid Inorganic materials 0.000 claims description 5
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 5
- 235000011118 potassium hydroxide Nutrition 0.000 claims description 5
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 5
- 239000001117 sulphuric acid Substances 0.000 claims description 5
- 235000011149 sulphuric acid Nutrition 0.000 claims description 5
- 239000008240 homogeneous mixture Substances 0.000 claims description 2
- 239000001828 Gelatine Substances 0.000 abstract 2
- 244000144730 Amygdalus persica Species 0.000 abstract 1
- 229920000084 Gum arabic Polymers 0.000 abstract 1
- 235000006040 Prunus persica var persica Nutrition 0.000 abstract 1
- 239000000205 acacia gum Substances 0.000 abstract 1
- 239000000305 astragalus gummifer gum Substances 0.000 abstract 1
- 229920000591 gum Polymers 0.000 abstract 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 abstract 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 abstract 1
- 239000002585 base Substances 0.000 description 51
- 239000007787 solid Substances 0.000 description 25
- 239000000047 product Substances 0.000 description 19
- 238000002360 preparation method Methods 0.000 description 13
- 230000036772 blood pressure Effects 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 10
- 102000030619 alpha-1 Adrenergic Receptor Human genes 0.000 description 8
- 108020004102 alpha-1 Adrenergic Receptor Proteins 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000001603 reducing effect Effects 0.000 description 7
- 239000007921 spray Substances 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 210000002307 prostate Anatomy 0.000 description 6
- 229960001909 terazosin hydrochloride Drugs 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000003002 pH adjusting agent Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000008859 change Effects 0.000 description 4
- 230000035487 diastolic blood pressure Effects 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 210000002460 smooth muscle Anatomy 0.000 description 4
- 101000748159 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 35 Proteins 0.000 description 3
- 206010043298 Testicular atrophy Diseases 0.000 description 3
- 102100040048 Ubiquitin carboxyl-terminal hydrolase 35 Human genes 0.000 description 3
- 201000010788 atrophy of testis Diseases 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000036513 peripheral conductance Effects 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- APKHJGDGWQDBGM-UHFFFAOYSA-N 6,7-dimethoxy-2-piperazin-1-ylquinazolin-4-amine Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N1CCNCC1 APKHJGDGWQDBGM-UHFFFAOYSA-N 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 229940127088 antihypertensive drug Drugs 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010071445 Bladder outlet obstruction Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 241000404317 Lindaconus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000031320 Teratogenesis Diseases 0.000 description 1
- 208000003800 Urinary Bladder Neck Obstruction Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000951 adrenergic alpha-1 receptor antagonist Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940030611 beta-adrenergic blocking agent Drugs 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000008571 general function Effects 0.000 description 1
- 231100000025 genetic toxicology Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- ITVGXXMINPYUHD-CUVHLRMHSA-N neohesperidin dihydrochalcone Chemical compound C1=C(O)C(OC)=CC=C1CCC(=O)C(C(=C1)O)=C(O)C=C1O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ITVGXXMINPYUHD-CUVHLRMHSA-N 0.000 description 1
- 235000010434 neohesperidine DC Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
- 229960001289 prazosin Drugs 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 229940070764 terazosin 1 mg Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 206010046459 urethral obstruction Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
Abstract
Description
Claims (10)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510320016.5A CN104840436B (en) | 2015-06-11 | 2015-06-11 | Pharmaceutical composition |
PCT/CN2016/080459 WO2016197738A1 (en) | 2015-06-11 | 2016-04-28 | Pharmaceutical composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510320016.5A CN104840436B (en) | 2015-06-11 | 2015-06-11 | Pharmaceutical composition |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104840436A true CN104840436A (en) | 2015-08-19 |
CN104840436B CN104840436B (en) | 2017-12-05 |
Family
ID=53840687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510320016.5A Active CN104840436B (en) | 2015-06-11 | 2015-06-11 | Pharmaceutical composition |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN104840436B (en) |
WO (1) | WO2016197738A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108272756A (en) * | 2018-04-09 | 2018-07-13 | 四川恒通动保生物科技有限公司 | A kind of amoxicillin soluble powder and preparation method thereof |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11224572B1 (en) | 2020-08-17 | 2022-01-18 | Novitium Pharma LLC | Stable oral liquid composition of terazosin |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1148810A (en) * | 1994-05-18 | 1997-04-30 | 千寿制药株式会社 | Medicinal composition for treating glaucoma |
US20050058696A1 (en) * | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
CN1616091A (en) * | 2004-09-17 | 2005-05-18 | 武汉大学 | Compound protease medicine for treating prostate proliferation and its preparing method |
CN101134023A (en) * | 2006-08-31 | 2008-03-05 | 海南海灵制药厂有限公司 | Hydrochloric acid terazosin oral cavity disintegrating lyophilized tablets and method for preparing the same |
CN101780054A (en) * | 2009-01-16 | 2010-07-21 | 江苏联环药业股份有限公司 | Compound sustained-release preparation and preparation method thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1732959A (en) * | 2005-08-17 | 2006-02-15 | 王兰周 | Guamecycline hydrochoride injection and preparation process thereof |
CN103976959B (en) * | 2013-02-07 | 2016-05-25 | 瑞阳制药有限公司 | Rifampin freeze-dried powder and preparation technology thereof |
-
2015
- 2015-06-11 CN CN201510320016.5A patent/CN104840436B/en active Active
-
2016
- 2016-04-28 WO PCT/CN2016/080459 patent/WO2016197738A1/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1148810A (en) * | 1994-05-18 | 1997-04-30 | 千寿制药株式会社 | Medicinal composition for treating glaucoma |
US20050058696A1 (en) * | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
CN1616091A (en) * | 2004-09-17 | 2005-05-18 | 武汉大学 | Compound protease medicine for treating prostate proliferation and its preparing method |
CN101134023A (en) * | 2006-08-31 | 2008-03-05 | 海南海灵制药厂有限公司 | Hydrochloric acid terazosin oral cavity disintegrating lyophilized tablets and method for preparing the same |
CN101780054A (en) * | 2009-01-16 | 2010-07-21 | 江苏联环药业股份有限公司 | Compound sustained-release preparation and preparation method thereof |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108272756A (en) * | 2018-04-09 | 2018-07-13 | 四川恒通动保生物科技有限公司 | A kind of amoxicillin soluble powder and preparation method thereof |
CN108272756B (en) * | 2018-04-09 | 2022-10-28 | 四川恒通动保生物科技有限公司 | Amoxicillin soluble powder and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2016197738A1 (en) | 2016-12-15 |
CN104840436B (en) | 2017-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6902583B2 (en) | Intranasal DHE for headache treatment | |
CN110139651A (en) | For treating the excessive composition of opioid and method | |
TW200906450A (en) | Method of producing pulverized organic compound particle | |
CN107405309B (en) | Tune for the orlistat and acarbose for the treatment of obesity and related metabolic disturbance releases composition | |
CN110248661A (en) | The treatment of prostate cancer | |
CN101868232B (en) | Lyophilized pharmaceutical composition with improved reconstitution time containing taxane derivatives and method of manufacturing the same | |
CN104902928A (en) | Co-micronisation product comprising ulipristal acetate | |
CN104721155B (en) | A kind of temozolomide freeze-dried powder preparation and preparation method thereof | |
CN104840436A (en) | Medicine composition | |
CN102481287B (en) | Pharmaceutical composition of temozolomide comprising vitamin c or vitamin c derivative and preparation method thereof | |
CN103330688B (en) | Ranitidine freeze-dried powder injection for curing gastropathy | |
CN104800172A (en) | Carbazochrome sodium sulfonate powder injection for injection and preparation method thereof | |
CN100464745C (en) | Medication composition of acetyl cysteine or its pharmaceutical salt and asarin | |
CN105106149B (en) | Levonorgestrel and its preparation method | |
WO2011006596A2 (en) | Aqueous solution and gelatinized composition comprising a phosphodiesterase-5 inhibitor and corresponding methods and use | |
CN101190937B (en) | Compound with liver-protecting activity | |
CN107157943A (en) | A kind of Topiroxostat preparation and preparation method thereof | |
WO2022216294A1 (en) | Powder for oral suspension containing tadalafil | |
TWI332403B (en) | ||
CN103315970B (en) | Ranitidine hydrochloride powder injection for injection | |
JP3995202B2 (en) | Turmeric composition for oral use | |
KR20210019402A (en) | Composition for injection | |
WO2017198224A1 (en) | Pharmaceutical composition of remimazolam | |
CN103638020A (en) | Novel pharmaceutical composition for treating gout | |
CN111714499B (en) | Pharmaceutical composition for treating polycystic ovarian syndrome |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200424 Address after: Room 116, Jinan biomedical industrial park, 1268 Gongye 4th Road, Bucun street, Zhangqiu District, Jinan City, Shandong Province Patentee after: Jinan anlianuo Enterprise Management Co.,Ltd. Address before: 100871 Beijing the Summer Palace Road, Haidian District, No. 5 Patentee before: Liu Lei |
|
TR01 | Transfer of patent right |
Effective date of registration: 20200525 Address after: Room 116, Jinan biomedical industrial park, 1268 Gongye 4th Road, Bucun street, Zhangqiu District, Jinan City, Shandong Province Patentee after: Shandong bangentei Biomedical Technology Group Co.,Ltd. Address before: Room 116, Jinan biomedical industrial park, 1268 Gongye 4th Road, Bucun street, Zhangqiu District, Jinan City, Shandong Province Patentee before: Jinan anlianuo Enterprise Management Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: Room 116, Jinan biomedical industrial park, 1268 Gongye 4th Road, Bucun street, Zhangqiu District, Jinan City, Shandong Province, 250219 Patentee after: Bonentai (Shandong) Biomedical Technology Group Co.,Ltd. Address before: Room 116, Jinan biomedical industrial park, 1268 Gongye 4th Road, Bucun street, Zhangqiu District, Jinan City, Shandong Province, 250219 Patentee before: Shandong bangentei Biomedical Technology Group Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220419 Address after: 250109 room 1-610, Lushang Phoenix Plaza, 4567 Tangye Middle Road, Jinan area, China (Shandong) pilot Free Trade Zone, Jinan City, Shandong Province Patentee after: Jinan anlianuo Enterprise Management Co.,Ltd. Address before: Room 116, Jinan biomedical industrial park, 1268 Gongye 4th Road, Bucun street, Zhangqiu District, Jinan City, Shandong Province, 250219 Patentee before: Bonentai (Shandong) Biomedical Technology Group Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220707 Address after: 100080 staff dormitory, No.5, Yiheyuan Road, Haidian District, Beijing Patentee after: Liu Lei Address before: 250109 room 1-610, Lushang Phoenix Plaza, 4567 Tangye Middle Road, Jinan area, China (Shandong) pilot Free Trade Zone, Jinan City, Shandong Province Patentee before: Jinan anlianuo Enterprise Management Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220801 Address after: 102445 room 904, floor 9, building 12, yard 2, Kechuang 6th Street, Beijing Economic and Technological Development Zone, Daxing District, Beijing (Yizhuang group, high-end industrial area of Beijing Pilot Free Trade Zone) Patentee after: Beijing Ansai Biotechnology Co.,Ltd. Address before: 100080 staff dormitory, No.5, Yiheyuan Road, Haidian District, Beijing Patentee before: Liu Lei |